Granules India Ltd (GRANULES.NS) trades near \u20b9583 with Q3 FY26 results scheduled for January 23, 2026, consensus expecting revenue \u20b91,377 Cr (+17.7% YoY), PAT \u20b9118 Cr (+21% YoY), EBITDA \u20b9174 Cr (+15%). EGM held January 22 for \u20b91,763 Cr fundraising approval.<\/p>\n
Detailed Technical Rationale (Buy-Side) Detailed Fundamental Analysis Micro & Macro View Key News Events & Impacts Additional Important Points Disclaimer & Disclosure Disclosure: No position\/holding in GRANULES as on Jan 22, 2026. Targets from technical\/fundamental models. Stop-loss mandatory. Market risks apply.<\/p>\n \u200b<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[388,386,400,130,121,92,128,116,127,155],"class_list":["post-26083","article","type-article","status-publish","hentry","article-category-learn","article-tags-calloptions","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-investment-opportunities","article-tags-sebi-registered-advisors","article-tags-sebi-registered-analysts","article-tags-signalzinvestmenttips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/26083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=26083"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=26083"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=26083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n<\/strong>Granules exhibits oversold bounce potential at \u20b9583.10 with RSI(14) 38.16 sell zone but CCI(14) -109 exhaustion signal, pivot \u20b9487.7 reference \u092a\u0930 S1 \u20b9473.54 \/ S2 \u20b9466.77 \/ S3 \u20b9454.54 strong support cluster aligning with 200-day SMA \u20b9514-520 neutral extension.
\nAll 12 MAs strong sell (10-day \u20b9602 \/ 50-day \u20b9575) \u0932\u0947\u0915\u093f\u0928 high volatility ATR 4.60 confirms capitulation bottom during pharma rotation. Volume accumulation targets R1 \u20b9597 \/ R2 \u20b9612 \/ R3 \u20b9621 resistance (2-6% upside) with stop below S3 \u20b9454 offering 1:4 risk-reward pre-results catalyst.<\/p>\n
\n<\/strong>Granules integrated pharma player Q2 FY26 revenue \u20b91,297 Cr (+35% YoY), EBITDA \u20b9278 Cr margins 21.4%, PAT growth via US API\/PFI exports 70% mix, debt reduction trajectory net cash positive potential. ROE 15%+, 10 ANDA filings pipeline strengthens complex generics moat.
\nFundraising \u20b91,763 Cr (warrants \u20b91,463 Cr @ \u20b9585 + equity \u20b9300 Cr) funds capex\/capacity expansion USFDA compliance, undervalued peers vs Nifty Pharma despite cyclical pressures, dividend payout history supports shareholder returns post-results.<\/p>\n
\n<\/strong>Micro View: Granules US-centric growth (90% exports), formulation expansion APIs\/PFIs\/FD, regulatory wins (FDA tentative approvals), new facilities commissioning offset Q2 one-offs, sticky customer concentration top-5 60% revenue stable.
\nMacro View: US pricing reforms tailwinds complex generics, PLI scheme electronics\/pharma incentives, rupee depreciation export boost; risks FDA observations, raw material volatility but hedged via long-term contracts.<\/p>\n
\n<\/strong>Q3 Results Jan 23, 2026 (Call 6 PM IST): Revenue +17.7% YoY \u20b91,377 Cr, PAT +21% \u20b9118 Cr, EBITDA +15% \u20b9174 Cr expected on export volumes\/margins. Watch USFDA updates, fundraising utilization guidance.
\nEGM Jan 22, 2026: Approved \u20b91,763 Cr preferential issue (promoters\/institutions), positive expansion signal but equity dilution ~10% risk.
\nKey Watch Levels: Pre-results \u20b9600 resistance break \u2192 \u20b9650 target; sub \u20b9473 breakdown \u2192 \u20b9450 test.<\/p>\n
\n<\/strong>Q2 strong execution despite headwinds validates guidance.
\n180-day exclusivity tentative FDA approvals pipeline catalyst.
\nCorrigendum EGM notice ensures compliance transparency.
\nNifty Pharma underperformance creates entry opportunity.<\/p>\n
\n<\/strong>Disclaimer:
\nThis constitutes research recommendation under SEBI (Research Analyst) Regulations 2014. Investogainer Research SEBI-registered RA; past performance no future guarantee. Independent verification required; no liability for losses.<\/p>\n